Wednesday, June 10, 2026

Patent intelligence · WO

WO 2025242585

FORMES CRISTALLINES DE SELS D'ÉLINZANÉTANT ET COMPOSITIONS CONTENANT DES SELS D'ÉLINZANÉTANT

granted A61P 5/ 24 A IA61P/524
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 25
Patent details — WO 2025242585

Quick answer

WO 2025242585 (FORMES CRISTALLINES DE SELS D'ÉLINZANÉTANT ET COMPOSITIONS CONTENANT DES SELS D'ÉLINZANÉTANT) is held by BAYER CONSUMER CARE AG [CH]. Status: granted. Granted Nov 27, 2025. Expires Nov 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61P 5/ 24 A I, A61P/524

More from BAYER CONSUMER CARE AG [CH]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026112109

    TECHNOLOGIE DE PLATEFORME DE GRANULATION PAR VOIE HUMIDE POUR FABRIQUER DES COMPRIMÉS/ARTICLES À MÂCHER MOUS

    BAYER HEALTHCARE LLC [US] · Expires May 23, 2046

    granted
  2. WO 2026106858

    FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES

    BAYER HEALTHCARE LLC [US] · Expires May 16, 2046

    granted
  3. EP 4741400

    MULTIMERE MANGANKONTRASTMITTEL

    BAYER AG [DE] · Expires May 8, 2046

    granted
  4. WO 2026068294

    PROCESSUS DE NANOENSEMENCEMENT AMÉLIORÉ

    BAYER AG [DE] · Expires Mar 28, 2046

    granted
  5. WO 2026047020

    FORMES CRISTALLINES D'INHIBITEURS DE HER2/MUTEGFR ET LEUR PROCÉDÉ DE PRÉPARATION

    BAYER AG [DE] · Expires Feb 28, 2046

    granted
  6. WO 2026047022

    FORME POSOLOGIQUE PHARMACEUTIQUE SOLIDE ET STABLE COMPRENANT UNE FORME CRISTALLINE D'UN INHIBITEUR DE HER2/MUTEGFR ET SA MÉTHODE DE PRÉPARATION

    BAYER AG [DE] · Expires Feb 28, 2046

    granted
  7. US 20260051027

    GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES

    BAYER AG [DE] · Expires Feb 14, 2046

    granted
  8. WO 2026032865

    SEL D'UN INHIBITEUR DE SOS-1

    BAYER AG [DE] · Expires Feb 7, 2046

    granted

Frequently asked questions

What is US patent 2025242585?

WO 2025242585 (FORMES CRISTALLINES DE SELS D'ÉLINZANÉTANT ET COMPOSITIONS CONTENANT DES SELS D'ÉLINZANÉTANT) is held by BAYER CONSUMER CARE AG [CH]. Status: granted. Granted Nov 27, 2025. Expires Nov 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2025242585?

BAYER CONSUMER CARE AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does WO 2025242585 expire?

Our index shows an expiration date of Nov 22, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.